Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) received FDA 510(k) clearance on March 2, 2026 for Surgiphor™ 1000mL, the first 1000 mL antimicrobial irrigation system designed for powered lavage. Surgiphor™ 1000mL is terminally sterile, ready-to-use, and built to integrate with common powered lavage devices to standardize wound irrigation and improve OR efficiency.
Key features include a powered-device adapter, Y-connector for quick switching, optimized flow with integrated venting, and a collapsible bottle for handling and evacuation.
Becton, Dickinson and Company (NYSE: BDX) announced pricing and accepted amounts for previously announced tender offers to purchase up to $2,000,000,000 aggregate principal amount (the Aggregate Offer Cap) of multiple series of its senior notes.
The company set Total Consideration per $1,000 for each series, will settle early on February 27, 2026 for early tenders, and allocated accepted principal by series (notable acceptances include $656,047,000 of 4.669% notes, $472,349,000 of 4.685% notes, $444,588,000 of 5.081% notes and $262,727,000 of 3.794% notes).
Becton, Dickinson and Company (NYSE: BDX) announced early tender results and an upsizing of its tender offers. The company increased the Aggregate Offer Cap from $1,600,000,000 to $2,000,000,000 and raised the Offer SubCap for its 4.685% Senior Notes due 2044. Withdrawal rights expired Feb 24, 2026; the company elected an Early Settlement Date of Feb 27, 2026. Securities accepted for purchase will be retired and cancelled. Total consideration will be determined by fixed spreads plus Treasury yields at 10:00 a.m. ET on Feb 25, 2026.
BD (NYSE: BDX) will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026 at 8:30 a.m. ET. The presentation will be webcast live and a replay will be posted on BD's investor relations website, investors.bd.com.
BD (NYSE: BDX) announced the BD Vacutainer® Urine Complete Cup Kit on February 23, 2026, a three-tube urine collection system designed to preserve specimen integrity, reduce repeat collections, and streamline testing workflows.
The kit includes culture, urinalysis, and discard tubes, a sterile cup with integrated transfer device, and a Castile wipe. Available in the United States with Hemogard and conventional stoppers and compatible with automated workflows; orders available through local sales representatives.
BD (NYSE: BDX) named Lanesha Minnix executive vice president and general counsel, effective March 16, 2026. Minnix will lead the Law Group and Public Affairs, report to Tom Polen, and join the BD Executive Leadership Team. She joins from Walgreens Boots Alliance, where she helped lead a $24 billion take-private transaction and oversaw legal, corporate affairs, risk, security and EHS. Minnix previously held senior roles at Ecolab and Flowserve and holds a JD and MBA from the University of Tulsa and a BS in Business Administration from Saint Louis University.
Becton, Dickinson and Company (NYSE: BDX) commenced tender offers to purchase up to $1,600,000,000 aggregate purchase price of specified outstanding senior notes across multiple series.
Key dates: Early Tender Date Feb 24, 2026, Reference pricing Feb 25, 2026, Expiration Mar 11, 2026, anticipated settlement Mar 13, 2026 (early settlement possible Feb 27, 2026). Early tender payments are $30 per $1,000 for eligible tenders. Offer SubCaps include $1,000,000,000 for 4.669% 2047 and $450,000,000 for one 2044 series. Acceptance priority levels and fixed spreads per series determine allocation and Total Consideration.
BD (NYSE: BDX) completed the spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters Corporation (NYSE: WAT) on Feb 9, 2026. BD received $4.0 billion in cash and shareholders received ~0.135 WAT shares per BDX share, with cash for fractions.
As of closing BD shareholders held 39.2% of the combined company (fully diluted). Based on WAT's Feb 6, 2026 close, the business was valued at $18.8 billion. BD expects to use $2.0 billion for an accelerated share repurchase and $2.0 billion to repay debt. Claire M. Fraser joined the Waters board and stepped down from the BD board.
Waters (NYSE: WAT) has completed its combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader organized into four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. The transaction used a Reverse Morris Trust, and post-close ownership is Waters 60.8% and BD shareholders 39.2% on a fully diluted basis. Claire M. Fraser, Ph.D., joined the Waters Board, expanding it to 11 members. Barclays advised Waters; Kirkland & Ellis served as lead counsel.
BD (NYSE: BDX) reported Q1 FY2026 revenue of $5.25B, up 1.6% reported (0.4% FXN), and reported diluted EPS $1.34 (+28.8%); adjusted diluted EPS was $2.91 (down 15.2%).
The company expects the Biosciences and Diagnostic Solutions combination with Waters to close Feb 9, 2026, and affirmed full-year New BD guidance: low single-digit revenue growth and adjusted diluted EPS of $12.35–$12.65.